<DOC>
	<DOCNO>NCT02277470</DOCNO>
	<brief_summary>The purpose study gain insight pharmacokinetics golimumab moderate severe Ulcerative Colitis subcutaneous administration , induction maintenance treatment investigator collect blood stool sample different time point .</brief_summary>
	<brief_title>Study Pharmacokinetics Golimumab Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description>The pharmacokinetic characteristic golimumab assess use blood stool sample ; collect induction maintenance treatment Patients undergo 13-16 blood sample collection , 13-16 stool sample collection 3 endoscopy 16 hospital visit 1 year . They also ask fill short questionnaire ( 9x ) . At endoscopy visit questionnaire regard quality life taken.The population pharmacokinetics golimumab assess use nonlinear mixed-effects model ( NON-MEM ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 18 year , either male female Moderate severe UC ( accord Mayo score ( 2 3 ) baseline endoscopy ) , antiTNF na√Øve antiTNF expose patient include Baseline endoscopy Obtained write informed consent Contraindication golimumab : TBC , severe infection congestive heart failure . Imminent need surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>pharmacokinetics , Golimumab , IBD</keyword>
</DOC>